What Is The Case For Waiting On Moderna Stock?

Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares reached their highest close in a year on October 15, 2026, ending the session at $236.50. Investors paying that premium are betting the drugmaker is ready to grow again. To meet those expectations, its sales, nearly all from COVID vaccines, have to stop shrinking, while its newer vaccines and cancer drugs have to start selling. Has the business caught up with Moderna's share pri